Inhibition of <scp>FcRn</scp> with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension
Nichola Cooper(Imperial College London), David J. Kuter(Harvard University), Rose Snipes(UCB Pharma (United States)), Birgit Haier(UCB Pharma (Germany)), James B. Bussel(NewYork–Presbyterian Hospital), Maciej Kaźmierczak(Silesian University of Technology), Andreea Lavrov(UCB Pharma (Germany)), Sarah Cluck, Yoshitaka Miyakawa(Keio University), Puneet Kumar Singh
Cited by 13
Related Papers
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
|Blood Advances|2019|1.1k
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Thrombocytopenia following Pfizer and Moderna <scp>SARS‐CoV</scp>‐2 vaccination
|American Journal of Hematology|2021|387